prikaz prve stranice dokumenta SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
  Download
PDF 1.26 MB
Scientific paper - Original scientific paper
SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
Plos pathogen, 17 (2021), 12; e1010175. https://doi.org/10.1371/journal.ppat.1010175
Chaouat, Abigael Eva; Achdout, Hagit; Kol, Inbal; Berhani, Orit; Roi, Gil; Vitner, Einat B.; Melamed, Sharon; Politi, Boaz; Zahavy, Eran; Brizić, Ilija; Lenac Roviš, Tihana; Alfi, Or; Wolf, Dana; Jonjić, Stipan; Israely, Tomer; Mandelboim, Ofer More authors...

Linked objects
COVID-19 (zbirka 2.) | Virtual collection
Cite this document

Chaouat, A. E., Achdout, H., Kol, I., Berhani, O., Roi, G., Vitner, E. B. ... Mandelboim, O. (2021). SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection. Plos pathogen, 17. (12). doi: 10.1371/journal.ppat.1010175

Chaouat, Abigael Eva, et al. "SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection." Plos pathogen, vol. 17, no. 12, 2021. https://doi.org/10.1371/journal.ppat.1010175

Chaouat, Abigael Eva, Hagit Achdout, Inbal Kol, Orit Berhani, Gil Roi, Einat B. Vitner, Sharon Melamed, et al. "SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection." Plos pathogen 17, no. 12 (2021). https://doi.org/10.1371/journal.ppat.1010175

Chaouat, A. E., et al. (2021) 'SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection', Plos pathogen, 17(12). doi: 10.1371/journal.ppat.1010175

Chaouat AE, Achdout H, Kol I, Berhani O, Roi G, Vitner EB, and sur.. SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection. Plos pathogen [Internet]. 2021 December 20 [cited 2024 September 16];17(12). doi: 10.1371/journal.ppat.1010175

A. E. Chaouat, et al., "SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection", Plos pathogen, vol. 17, no. 12, December 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:864171. [Accessed: 16 September 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
AuthorAbigael Eva Chaouat
AuthorHagit Achdout
AuthorInbal Kol
AuthorOrit Berhani
AuthorGil Roi
AuthorEinat B. Vitner
AuthorSharon Melamed
AuthorBoaz Politi
AuthorEran Zahavy
AuthorIlija Brizić
AuthorTihana Lenac Roviš
AuthorOr Alfi
AuthorDana Wolf
AuthorStipan Jonjić
AuthorTomer Israely
AuthorOfer Mandelboim
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Center for Proteomics)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Currently, as dangerous mutations emerge, there is an increased demand for specific treatments for SARS-CoV-2 infected patients. The spike glycoprotein on the virus envelope binds to the angiotensin converting enzyme 2 (ACE2) on host cells through its receptor binding domain (RBD) to mediate virus entry. Thus, blocking this interaction may inhibit viral entry and consequently stop infection. Here, we generated fusion proteins composed of the extracellular portions of ACE2 and RBD fused to the Fc portion of human IgG1 (ACE2-Ig and RBD-Ig, respectively). We demonstrate that ACE2-Ig is enzymatically active and that it can be recognized by the SARS-CoV-2 RBD, independently of its enzymatic activity. We further show that RBD-Ig efficiently inhibits in-vivo SARS-CoV-2 infection better than ACE2-Ig. Mechanistically, we show that anti-spike antibody generation, ACE2 enzymatic activity, and ACE2 surface expression were not affected by RBD-Ig. Finally, we show that RBD-Ig is more efficient than ACE2-Ig at neutralizing high virus titers. We thus propose that RBD-Ig physically blocks virus infection by binding to ACE2 and that RBD-Ig should be used for the treatment of SARS-CoV-2-infected patients.
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titlePlos pathogen
Numberingvol. 17, no. 12, e1010175
p-ISSN1553-7374
e-ISSN1553-7374
DOIhttps://doi.org/10.1371/journal.ppat.1010175
URN:NBNurn:nbn:hr:184:864171
Publication2021-12-20
ProjectNumber: IP-CORONA-2020-04-2073
Title (croatian): Dosta skrivanja CoV-2: uspostava baze monoklonskih protutijela na SARS-Cov-2
Title (english): No more hiding CoV-2: Establishment of SARS-Cov-2 mAbeom
Acronym: CoV2mAbs
Leader: Ilija Brizić
Jurisdiction: Croatia
Funding stream: IP-CORONA
ProjectNumber: KK.011.1.01.0006
Title (croatian): Jačanje kapaciteta CerVirVac-a za istraživanja u virusnoj imunologiji i vakcinologiji
Leader: Stipan Jonjić
Jurisdiction: eu
ProjectNumber: N/A
Title (croatian): Centar izvrsnosti za virusnu imunologiju i cjepiva
Title (english): Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines
Acronym: CERVirVac
Leader: Stipan Jonjić
Jurisdiction: Croatia
Funding stream: ZCI
Document URLhttps://dx.plos.org/10.1371/journal.ppat.1010175
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-04-06 11:24:16